These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25899771)

  • 1. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
    Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
    Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
    Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
    Nishikawa H; Tsudo M; Osaki Y
    Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
    Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.
    Ochi Y; Kazuma Y; Hiramoto N; Ono Y; Yoshioka S; Yonetani N; Matsushita A; Imai Y; Hashimoto H; Ishikawa T
    Ann Hematol; 2017 Jan; 96(1):1-8. PubMed ID: 27641425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
    Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
    Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
    Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma.
    Gao R; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Yang T; Xu W
    Int J Cancer; 2018 Oct; 143(8):1884-1895. PubMed ID: 29744861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.
    Jelicic J; Juul-Jensen K; Bukumiric Z; Runason Simonsen M; Roost Clausen M; Ludvigsen Al-Mashhadi A; Schou Pedersen R; Bjørn Poulsen C; Ortved Gang A; Brown P; El-Galaly TC; Larsen TS
    Cancer Med; 2024 Jun; 13(12):e7239. PubMed ID: 38888359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
    Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
    Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
    Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
    Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.